Loading...
XNAS
CBUS
Market cap86mUSD
Jul 09, Last price  
1.90USD
1D
4.40%
1Q
25.83%
IPO
-92.71%
Name

Cibus Global Ltd

Chart & Performance

D1W1MN
XNAS:CBUS chart
P/E
P/S
23.75
EPS
Div Yield, %
Shrs. gr., 5y
-7.55%
Rev. gr., 5y
-31.34%
Revenues
4m
-14.62%
1,272,000399,000508,000236,0007,296,00023,851,00025,987,000157,0001,817,0004,262,0003,639,000
Net income
-127m
L-49.45%
-5,889,000-12,086,000-25,980,000-27,897,000-39,612,000-44,836,000-29,199,000-16,891,000-267,627,000-251,388,000-127,085,000
CFO
-51m
L-12.84%
-6,691,000-9,237,000-12,785,000-20,252,000-31,951,000-43,672,000-18,811,000-19,364,000-46,210,000-58,043,000-50,591,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients. it has patented core technology platform, RTDS, a scalable, standardized, end-to-end, semi-automated and high-throughput gene-editing system marketed under the Trait Machine brand name. The company was formerly known as Calyxt, Inc. and changed its name to Cibus, Inc. in June 2023. Cibus, Inc. was incorporated in 2010 and is headquartered in San Diego, California.
IPO date
Feb 15, 2019
Employees
Domiciled in
US
Incorporated in
VG

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT